Baxter has formed an agreement with India-based Dorizoe Lifesciences, a full-service global contract research and development (R&D) organization, designed to facilitate accelerated development of more than 20 generic injectable products, including anti-infectives, oncolytics and cardiovascular medicines. Dorizoe will work with Baxter to perform certain product development activities, and Baxter will hold worldwide manufacturing and commercialization rights. “This partnership extends Baxte...